Carregant...
Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies
BACKGROUND: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). SCOPE: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select patients th...
Guardat en:
| Publicat a: | Drugs Context |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioExcel Publishing Ltd
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5699107/ https://ncbi.nlm.nih.gov/pubmed/29167692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212506 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|